

Impaired Antiviral Response and Alpha/Beta Interferon Induction in Mice Lacking Beta Interferon

RAJ DEONARAIN,¹ ANTONIO ALCAMI,² MARIA ALEXIOU,¹ MARGARET J. DALLMAN,³
DIRK R. GEWERT,^{4*} AND ANDREW C. G. PORTER^{1*}

MRC Clinical Science Centre, Imperial College School of Medicine, Hammersmith Hospital, London W12 0NN,¹
Division of Virology, Department of Pathology, Cambridge University, Cambridge CB2 1QP,² Department
of Biology, Imperial College of Science Technology and Medicine, South Kensington, London
SW7 2AZ,³ and QT Genetics Ltd., Cambridge CB4 3GA,⁴ United Kingdom

Received 8 September 1999/Accepted 30 December 1999

We have generated mice lacking the gene for beta interferon and report that they are highly susceptible to vaccinia virus infection. Furthermore, in cultured embryo fibroblasts, viral induction of alpha interferon and of 2-5A synthetase genes is impaired. We also show that beta interferon does not prime its own expression.

Interferons (IFNs) consist of a family of evolutionarily conserved proteins encoded by closely related and linked genes. Alpha/beta IFNs (IFN- α/β), represented by several IFN- α subtypes, IFN- β , and IFN- ω , bind to a common cell surface receptor, resulting in the activation of the Jak-STAT signal transduction system (7, 8) and leading to the transcriptional activation of IFN-stimulated genes. The products of these genes must account not only for the versatile antiviral effects of IFNs but also for their immunomodulatory and antiproliferative effects. The roles of some of these proteins, including 2-5A synthetase, in establishing an antiviral state have been described (25, 34, 38).

IFN plays an important role in the protection against infection by a large number of viruses, including vaccinia virus and other poxviruses (39). This is emphasized by the expression of a number of different anti-interferon strategies by viruses, including soluble IFN receptors and intracellular proteins that block the activities of key interferon-inducible genes (40).

IFN- α/β are expressed by cells within hours of infection by virus and can act in an autocrine or paracrine manner to limit the development and spread of viral infection. This primary role for IFN- α/β in vivo is confirmed in studies with mice lacking one of the two chains of the functional IFN- α/β receptor: these animals display an extreme sensitivity to infection by viral pathogens. However, these studies did not differentiate between the roles of IFN- α and IFN- β in the antiviral response (44).

Despite these advances in our knowledge, our understanding of the IFN- α/β system is still far from complete. First, it is not known why there are so many IFN- α/β genes. In mice, there are at least 12 IFN- α genes and a single IFN- β gene clustered on chromosome 4 (18), and the protein product of any one of these appears to be sufficient to generate an antiviral state in responsive cells (19). Second, it is not known how the role of IFN- β differs from that of the various IFN- α subtypes. Whereas the murine IFN- α genes have ~90% homology, murine IFN- β appears to be rather more divergent, with only ~55% homology to a murine IFN- α consensus sequence.

Third, the exact nature of the inducers for IFN- α/β is uncertain. It is known that double-stranded RNA, produced during a variety of viral infections, can induce transcription of IFN- α/β genes, but nonviral inducers have also been described (4, 36, 41). Induction of the IFN β gene has been extensively studied in cell culture, leading to a detailed knowledge of *cis*-acting sequences and binding factors required for transcriptional induction (16); a similar but less complete analysis of IFN- α induction has been carried out (27). Nonetheless, the precise nature of the inducer for particular viral infections is unknown and details of the pathway(s) leading to transcriptional activation are still sketchy. Finally, the importance of the kinetics of IFN- α/β induction and the identity of the cellular source of IFN- α/β induction during an in vivo infection are unclear. Thus, although it is known that IFN- α/β can be induced in a wide variety of cell types, it is unclear whether induction in the initially infected cell type is sufficient for a proper defense or whether paracrine IFN activity on other cell types is important.

We reasoned that a mouse in which the endogenous IFN- β genes have been deleted would be useful in determining whether IFN- α can compensate for the loss of IFN- β . Furthermore, by replacing the IFN- β gene with a reporter, the same mice should yield information concerning the source, control, and timing of IFN- β gene expression. In a similar approach, another group (13) provided evidence for a role for IFN- β in IFN- α induction but did not establish whether the effect was of physiological significance.

Generation and preliminary analysis of IFN- $\beta^{-/-}$ mice. Targeting constructs were designed to delete the IFN- β gene and replace it with a reporter gene for green fluorescent protein (GFP) (30) or hCD2 (26) (Fig. 1a and b). The virus inducibility of the reporter genes was confirmed in human 293 cells stably transfected with these constructs (Fig. 1c and d). HM-1 embryonic stem cells (22) transfected with the constructs were screened by Southern blotting (46) and targeted clones were detected at a frequency of about 1 per 40 G418-resistant clones (Fig. 1e and f). Several targeted clones were separately injected into C57BL/6 blastocysts, and resulting chimeric mice were tested for germ line transmission of the transgene in crosses with C57BL/6 mice. One chimera carrying the Mu β GFP/neo transgene showed efficient germ line transmission, and F1 heterozygotes from this chimera were identified by PCR analysis of tail biopsies. These IFN- $\beta^{+/-}$ offspring were crossed to generate IFN- $\beta^{+/+}$, IFN- $\beta^{+/-}$, and IFN- $\beta^{-/-}$ F2 pups as well as mouse embryo fibroblasts (MEFs) (17).

* Corresponding authors. Mailing address for Andrew C. G. Porter: Gene Targeting Group, MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Rd., London W12 0NN, United Kingdom. Phone: 44 181 383 8276. Fax: 44 181 383 8303. E-mail: andy.porter@csc.mrc.ac.uk. Phone for D. R. Gewert: 44 223 575527. Fax: 44 223 575528. E-mail: gewert@dialstart.net.




FIG. 1. Design and use of *IFNβ* targeting constructs and genotyping of MEFs from an ES clone targeted with pMuβGFP/neo. Details of plasmid construction and conditions for cell growth and transfection are described elsewhere (9). (a) The targeting construct pMuβGFP/neo (*NotI* linearized; top), the *IFNβ* locus (center), and the product of homologous recombination between them (bottom) are represented as follows: *IFNβ* gene (black box), *IFNβ* promoter region (ellipse), other DNA from the *IFNβ* locus (thick black lines), GFP gene (white box; from pRSGFP [Clontech]), *neo* cassette (stippled box), *loxP* site (black triangle), and pBSKSII+ DNA (thin line). Key sites for *Bam*HI (B) and resulting fragments detectable by probe a (a black bar) are shown. (b) As for panel a except for targeting construct pMuβCD2/neo; white box represents human CD2 gene. (c) Flow cytometric analysis of GFP expression in a G418-resistant 293 clone stably transfected with pMuβGFP/neo, either without induction or 48 h after induction by Sendai virus infection. (d) Flow cytometric analysis of CD2 expression in a pool of 293 G418-resistant clones stably transfected with pMuβCD2/neo, either without induction or 48 h after induction by Sendai virus infection. Conditions for electroporation, infection, and flow cytometry in panels c and d have been previously described (9) and are available on request. (e) Screening by Southern analysis for ES cell clones targeted with pMuβGFP/neo (18, 22). Analysis of *Bam*HI-digested DNA from 10 G418-resistant clones probed with probe a. The 7.3-kb band representing the unmodified *IFNβ* locus migrates differently in odd- and even-numbered lanes because one comb was used for odd lanes and another for even lanes. A targeted clone and its diagnostic band are indicated by vertical and horizontal arrows, respectively. (f) As for panel e but with targeting construct pMuβCD2/neo. (g) Duplex PCR detection of *IFNβ* and *GFP* genes in genomic DNA. ND, no template DNA. (h) Southern analysis of *Bam*HI-digested MEF DNA probed with probe a or *IFNβ* probe (a 460-bp *Bam*HI-*Kpn*I fragment of the *IFNβ* gene). Size markers (M) are shown.

Genotypes of pups and MEFs were determined by PCR (Table 1) as illustrated for MEFs in Fig. 1g. In addition, Southern analyses of DNA from the MEFs showed the expected pattern of bands diagnostic for normal and targeted *IFNβ* genes (Fig. 1h). The MEFs were also tested by reverse transcription-PCR (RT-PCR) for *IFNβ* and *GFP* mRNA induction following viral infection. As expected, *IFNβ* expression was not detected in *IFNβ*^{-/-} MEFs, while a clear virus-inducible signal

was detected in both *IFNβ*^{+/-} and *IFNβ*^{+/+} MEFs. Similarly, GFP expression was detectable following virus induction of both *IFNβ*^{+/-} and *IFNβ*^{-/-} MEFs but was not detected at all in *IFNβ*^{+/+} MEFs (Fig. 2). The GFP reporter was therefore under the control of the virus inducible elements of the *IFNβ* gene locus. A further observation from the induction of these MEF cells is that the inducibility of the GFP reporter is apparently the same in both *IFNβ*^{+/-} and *IFNβ*^{-/-} cells. This suggests that *IFNβ* does not have any marked effect on the inducibility of the *IFNβ* promoter following virus induction. This contrasts with the transcription-enhancing activity reported by others (12, 20) for *IFN-α/β* on the *IFNβ* regulatory elements.

Increased susceptibility of *IFNβ*^{-/-} mice to viral infection. Because of the central role of *IFN-α/β* in host response to viral infection, we investigated the effect of deletion of the *IFNβ* gene on the progression of vaccinia virus infection. Following intranasal inoculation at three doses of virus, the course of infection was monitored by measuring weight loss and other indicators of infection, as previously described (2, 42). The results (Fig. 3) show a dramatically increased susceptibility to infection in *IFNβ*^{-/-} mice. At the lowest virus inoculum (10^3 PFU/animal), *IFNβ*-deficient mice showed signs of illness and weight loss and a single animal died. All other animals showed no signs of disease, cleared the infection, and recovered the initial weight loss. At both 10^4 and 10^5 PFU/animal, all the *IFNβ*-deficient mice succumbed to the infection after rapid weight loss and severe signs of illness. By contrast, the *IFNβ*^{+/+} mice were more resistant to vaccinia virus, showing minor signs of illness and recovering from the infections, except for a single mortality at the intermediate virus dose. These data indicated that the *IFNβ*^{-/-} animals are highly susceptible to vaccinia virus infection and succumb to doses that are sublethal to animals able to express *IFNβ*.

The replication of vaccinia virus in different organs of mice was also investigated (Fig. 4). The lower doses of viral inoculum (10^3 PFU/animal) resulted in significantly higher titers of virus in the *IFNβ*^{-/-} mice than in *IFNβ*^{+/+} animals, and this was particularly evident at the primary site of infection, the lungs. This difference in vaccinia virus replication was less evident at the higher inoculum tested (10^4 PFU/animal): at day 6 postinfection, vaccinia virus had replicated to similar levels in the absence or presence of *IFNβ*. It is interesting, however, that the *IFNβ*^{+/+} mice recovered from the infection at 10^4 PFU/animal whereas the *IFNβ*^{-/-} animals succumbed (Fig. 3). This suggests that *IFNβ* may play a role in the recovery from an established vaccinia virus infection.

Impaired *IFN-α/β* response in *IFNβ*^{-/-} MEFs. As an indicator of the antiviral response, we used RT-PCR to measure induction of the gene encoding 2-5A synthetase in MEFs infected with virus. The results show a clear difference between *IFNβ*^{-/-} MEFs, in which 2-5A gene expression was weak, and *IFNβ*^{+/-} and *IFNβ*^{+/+} MEFs, in which a robust induction was detected (Fig. 2). To explore the possible basis for the poor induction of 2-5A synthetase in *IFNβ*^{-/-} MEFs, we measured *IFN-α* induction in the same RNA samples, again by RT-PCR. A recent study (23) has indicated that the *IFN-α*-4 subtype is induced earlier than other *IFN-α* subtypes in response to viral induction. An RT-PCR was therefore designed to detect all known *IFN-α* transcripts (*Uα*), another specific for the *IFN-α*-4 subtype (*α4*), and a third to detect all *IFN-α* transcripts except *IFN-α*-4 (Non-*α4*); all showed detectable induction in *IFNβ*^{-/-} MEFs, although the response was clearly impaired compared to that in *IFNβ*^{+/+} and *IFNβ*^{+/-} MEFs (Fig. 2). The relatively low levels of the various *IFN-α* transcripts detected in RNA from *IFNβ*^{-/-} MEFs was not caused by a low quality or

TABLE 1. PCR primers used in this study

Gene (assay)	Primers ^a	Cycles [no. (°C/s)]	MgCl ₂ (mM)	Product size (bp)
IFN-β (genotyping)	5'-TGGGAAATTCCTCTGAGGCAG-3' (S) 5'-CACTCATTCTGAGGCATCAACTGAC-3' (A)	35 (94/30, 60/30, 72/60)	1.5-3	717
GFP (genotyping)	5'-GGTGAAGGTGATGCAACATACGG-3' (S) 5'-TGTGGACAGGTAATGGTTGTCTGG-3' (A)	35 (94/30, 60/30, 72/60)	1.5-3	513
IFN-β (RT-PCR)	5'-ACACAAGCTTAACCACCATGAACAACAGGTGGATCCTCCACGC-3' (S) 5'-GTTAGGAATTCTCAGTTTTTGGAAAGTTTCTGGTAAAGTCTTCG-3' (A)	30 (94/30, 60/30, 72/60)	3	560
GFP (RT-PCR)	5'-GGTGAAGGTGATGCAACATACGG-3' (S) 5'-TGTGGACAGGTAATGGTTGTCTGG-3' (A)	30 (94/30, 60/30, 72/60)	3	513
Universal IFN-α	5'-ATGGCTAGGCYCTGTGCTTTC-3' (S) 5'-TCTGAYCACCTCCCAGGCACA-3' (A)	30 (94/60, 50/120, 72/180)	1.5	~500
IFN-non-α4	5'-ARSYTGTSTGATGCARCAGGT-3' (S) 5'-GGWACACAGTGATCCTGTGG-3' (A)	30 (94/30, 55/30, 72/30)	1.5	~104
IFN-α4	5'-CTGGTCAGCCTGTTCTTAGGATG-3' (S) 5'-TCAGAGGAGGTTCCGCATCAC-3' (A)	30 (94/30, 55/30, 72/30)	1.5	314
2-5A synthetase	5'-CCCCATCTGCATCAGGAGGTGGAG-3' (S) 5'-AAGTCATAATACTTTGTCCAGTAG-3' (A)	30 (94/30, 58/60, 72/60)	1.5	422
PGK	5'-CCTCCGCTTTCATGTAGAGGAAGA-3' (S) 5'-GTAAAGGCCATTCCACCACCAA-3' (A)	30 (94/60, 55/60, 72/60)	1.5	400

^a S, sense; A, antisense.

quantity of IFN-β^{-/-} RNA: control RT-PCR assays for transcripts encoding the housekeeping enzyme phosphoglycerate kinase (PGK) showed no difference between IFN-β^{-/-}, IFN-β^{+/-}, and IFN-β^{+/+} MEFs (Fig. 2). While the signal for Non-α4 transcripts was particularly weak in IFN-β^{-/-} cells, it was clearly higher at 12 h than at 0 h after infection. It therefore

appears that all IFN-α genes are at least partially dependent on IFN-β for induction, although it remains possible that some species (e.g., Non-α4) are more dependent than others (e.g., α4).

The key finding in this report is that IFN-β is required to mount an antiviral response following infection of mice with vaccinia virus. Mice deficient in the IFN-α/β receptor have




FIG. 2. RT-PCR assays for induction of IFN-α/β, GFP, and 2-5A synthetase transcripts in IFN-β^{+/+}, IFN-β^{+/-}, and IFN-β^{-/-} MEFs. MEFs were infected with Sendai virus and harvested for RNA preparation either immediately (0 h) or 12 h later, as indicated. RNA (1 μg), prepared by lysis in guanidium isothiocyanate and density gradient centrifugation, was reverse transcribed (15-μl reaction mixtures containing avian myeloblastosis virus reverse transcriptase [Promega Biotech]) and, after the indicated dilutions, RT products (1 μl) were assayed by PCR for the following cDNAs: IFN-β, GFP, 2-5A synthetase (2-5AS), all known IFN-α subtypes (Uα), IFN-α4 subtype (α4), all known IFN-α subtypes excluding IFN-α4 (Nα4) and, as a positive control, phosphoglycerate kinase (PGK). Conditions for PCRs are summarized in Table 1.




FIG. 3. Vaccinia virus infection in $IFN-\beta^{+/+}$ and $IFN-\beta^{-/-}$ mice. Groups of 7- to 9-week-old $IFN-\beta^{+/+}$ (open circles) or $IFN-\beta^{-/-}$ mice (closed circles) were intranasally infected with 10^3 , 10^4 , or 10^5 PFU of vaccinia virus strain Western Reserve. Every day, mice were individually weighed and monitored for signs of illness, scored from zero to four (ruffled fur, arched backs, and reduced mobility), or death. The mean percentage weight loss of each group \pm the standard error of the mean, relative to the weight immediately preceding the infection, and the mean value of signs of illness \pm the standard error of the mean in groups of mice infected with the indicated doses of virus, are shown. The horizontal bars indicate those days in which differences were statistically significant when analyzed by Student's t test, and the P values are shown. The number of mice per group that either died or were sacrificed due to severe infection is shown in the insets.

been reported to be more susceptible to viral infections, including vaccinia virus (43). However, because all $IFN-\alpha/\beta$ sub-species are induced under broadly similar conditions, act through a single receptor system, and have each been shown to have antiviral activities, the *in vivo* antiviral effect could be mediated by any or all $IFN-\alpha/\beta$ molecules, singly or in combination. The infection of $IFN-\beta^{-/-}$ mice with vaccinia virus provided an opportunity to evaluate the specific *in vivo* role of $IFN-\beta$ in host defenses. The increased susceptibility of these animals to vaccinia virus was striking because the $IFN-\alpha$ s might be expected to compensate for loss of the single $IFN\beta$ gene. That this is not the case indicates that $IFN-\beta$ performs some unique role that is essential for a full antiviral response.

At least two mechanisms can be envisaged to explain such a unique role for $IFN-\beta$. In the first, $IFN\alpha$ and $IFN\beta$ genes may be independently induced by viral infection, but $IFN-\beta$ may specifically induce one or more genes that are required for full antiviral activity. Consistent with this possibility, there is evidence for $IFN-\beta$ -specific signalling via the alpha/beta receptor (1, 6, 11, 28, 29, 33) and, in human fibrosarcoma cells at least, for a set of genes (including that encoding the double-stranded RNA-activated protein kinase, whose antiviral activity has been well studied [38]) that are preferentially or exclusively induced by $IFN-\beta$ (10, 31). On its own, however, this model does not explain our observation, and that of others (13), that $IFN-\alpha$ induction is impaired in $IFN-\beta^{-/-}$ MEFs. A second mechanism that does not rely on differential signaling by $IFN-\beta$ and $IFN-\alpha$ is suggested by this observation. Thus, it is possible that only $IFN\beta$ is induced directly by viral infection and that $IFN-\alpha$ induction is a consequence of this initial $IFN-\beta$ expression. Previous work showing that induction of $IFN\alpha$, but not $IFN\beta$, requires protein synthesis (14) is consistent with this model, as are data (21, 35, 37, 45, 47) describing a direct

pathway for $IFN\beta$ induction by virus involving the transcription factor IRF-3. In a combination of these two mechanisms, viral infection might directly induce only $IFN-\beta$ expression, and differential signaling by $IFN-\alpha$ and $IFN-\beta$ could still be possible, with $IFN-\beta$ specifically inducing $IFN-\alpha$ expression. The interesting observation that, in mice, $IFN-\alpha$ can be induced by $IFN-\beta$ but $IFN-\beta$ cannot be induced by $IFN\alpha$ (3), is probably most compatible with this model. Further experiments, including the injection of specific $IFN-\alpha/\beta$ subtypes into infected $IFN-\beta^{-/-}$ mice, are required to test these possibilities.




FIG. 4. Vaccinia virus replication in $IFN-\beta^{+/+}$ and $IFN-\beta^{-/-}$ mice (7 to 9 weeks old). Groups of $IFN-\beta^{+/+}$ (open circles) and $IFN-\beta^{-/-}$ mice (closed circles) were infected intranasally with 10^3 or 10^4 PFU of vaccinia virus strain Western Reserve per animal as previously described (2, 42). On the indicated days postinfection, animals were sacrificed and infectious virus in Dounce-homogenized lungs, spleen, and brain was determined by plaque titration on BS-C-1 cell monolayers. The geometric mean (\bar{x}) and titers in independent mice, expressed as PFU per organ, are presented. The dashed line indicates the detection limit of the assay.

Vaccinia virus encodes a number of strategies to block IFN responses, including a soluble receptor for IFN- α/β (5, 42) that needs to be considered when interpreting results from infected mice. The vaccinia virus IFN- α/β receptor expressed from the strain Western Reserve binds to both mouse IFN- α and IFN- β with lower affinity than to the corresponding human IFNs (42). Furthermore, recent data indicate that this receptor does not block the antiviral effects of mouse IFN- β , suggesting a poor affinity for this species in vivo (V. P. Smith and A. Alcami, unpublished data). Thus, in the mouse model we have used here, vaccinia virus does not modify the function of IFN- β .

A very recent study (23) has shown the *IFN α 4* gene to differ from other *IFN α* genes and to be similar to the *IFN β* gene in its being induced particularly rapidly and without the need for de novo protein synthesis. It was also shown that *IFN α* genes other than *IFN α 4* require Stat1 for induction. Other recent studies (21, 35, 37, 45, 47) have shown induction of *IFN β* to require viral modification of preexisting transcription factor IRF-3. It was therefore proposed (23) that *IFN β* and *IFN α 4* are induced as a primary response to viral infection, via a pathway involving IRF-3 phosphorylation, and that secreted IFN- β and IFN- α 4 cause induction of the remaining *IFN α* genes via the type I receptor and the Jak-STAT pathway. Our data are only partly consistent with this model. Clearly some IFN- α inducibility remains in the absence of IFN- β and it is possible that this remaining induction represents the predicted IFN- α 4-dependent component. However, the fact that induction of IFN- α 4 itself is markedly compromised in the absence of IFN- β does not support a direct, and therefore presumably IFN- β -independent, mechanism for IFN- α 4 induction. Clearly, further experiments including deletion of the *IFN α 4* gene are required to resolve these issues.

One of the aims of this study was to place a reporter gene at the *IFN β* locus so that the kinetics and cellular origin of IFN- β could be studied during an infection in vivo. Recent reports show that both GFP (15, 24) and CD2 (32) can be used successfully as reporters in targeted mice. We showed that the *GFP* or *CD2* reporter genes in the targeting constructs are induced by viral infection in human cells even when randomly inserted into the genome (Fig. 1c and d). RT-PCR analyses showed further that induction of GFP transcripts occurred in MEFs derived from targeted mice (Fig. 2). So far, however, we have been unable to detect GFP fluorescence by flow cytometry in virus-infected MEFs, although we have detected the induction of GFP in Western blots (R. Deonarain, unpublished results). It appears that a different form of GFP is required for the detection of GFP fluorescence in targeted MEFs, although targeted cell types that normally express IFN- β more abundantly than MEFs may yet allow induction to be followed by fluorescence.

We thank Neil A. Bryant and Zoe Webster for technical assistance and David Melton for providing HM-1 cells.

This work was funded by an MRC/GlaxoWellcome joint studentship (R.D.) and the Wellcome Trust. A.A. is a Wellcome Trust Senior Research Fellow.

REFERENCES

- Abramovich, C., J. Chebath, and M. Revel. 1994. The human interferon alpha-receptor protein confers differential responses to human interferon-beta versus interferon-alpha subtypes in mouse and hamster cell transfectants. *Cytokine* **6**:414-424.
- Alcami, A., and G. L. Smith. 1992. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. *Cell* **71**:153-167.
- Asano, M., M. Hayashi, E. Yoshida, Y. Kawade, and Y. Iwakura. 1990. Induction of interferon-alpha by interferon-beta, but not of interferon-beta by interferon-alpha, in the mouse. *Virology* **176**:30-38.
- Billiau, A., M. Joniau, and P. De Somer. 1973. Mass production of human interferon in diploid cells stimulated by poly-I:C. *J. Gen. Virol.* **19**:1-8.
- Colamonic, O. R., P. Domanski, S. M. Sweitzer, A. Larner, and R. M. Buller. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. *J. Biol. Chem.* **270**:15974-15978.
- Croze, E., D. Russell Harde, T. C. Wagner, H. Pu, L. M. Pfeffer, and H. D. Perez. 1996. The human type I interferon receptor. Identification of the interferon beta-specific receptor-associated phosphoprotein. *J. Biol. Chem.* **271**:33165-33168.
- Darnell, J. E., Jr. 1997. STATs and gene regulation. *Science* **277**:1630-1635.
- Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science* **264**:1415-1421.
- Deonarain, R. K. 1999. Ph.D. thesis. University of London, London, United Kingdom.
- Der, S. D., A. Zhou, B. R. Williams, and R. H. Silverman. 1998. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. *Proc. Natl. Acad. Sci. USA* **95**:15623-15628.
- Domanski, P., O. W. Nadeau, L. C. Platanius, E. Fish, M. Kellum, P. Pitha, and O. R. Colamonic. 1998. Differential use of the betaL subunit of the type I interferon (IFN) receptor determines signaling specificity for IFNalpha2 and IFNbeta. *J. Biol. Chem.* **273**:3144-3147.
- Dron, M., M. Lacasa, and M. G. Tovey. 1990. Priming affects the activity of a specific region of the promoter of the human beta interferon gene. *Mol. Cell. Biol.* **10**:854-858.
- Erlansson, L., R. Blumenthal, M. L. Eloranta, H. Engel, G. Alm, S. Weiss, and T. Leanderson. 1998. Interferon-beta is required for interferon-alpha production in mouse fibroblasts. *Curr. Biol.* **8**:223-226.
- Gobl, A. E., B. Cederblad, K. Sandberg, and G. V. Alm. 1992. Interferon-alpha but not -beta genes require de novo protein synthesis for efficient expression in human monocytes. *Scand. J. Immunol.* **35**:177-185.
- Godwin, A. R., H. S. Stadler, K. Nakamura, and M. R. Capecchi. 1998. Detection of targeted GFP-Hox gene fusions during mouse embryogenesis. *Proc. Natl. Acad. Sci. USA* **95**:13042-13047.
- Hiscott, J., H. Nguyen, and R. Lin. 1995. Molecular mechanisms of interferon beta gene induction. *Semin. Virol.* **6**:161-173.
- Hogan, B., R. Beddington, F. Constantini, and E. Lacy. 1994. *Manipulating the mouse embryo: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Kelley, K. A., and P. M. Pitha. 1985. Characterization of a mouse interferon gene locus. I. Isolation of a cluster of four alpha interferon genes. *Nucleic Acids Res.* **13**:805-823.
- Kelley, K. A., N. B. Raj, M. Kellum, and P. M. Pitha. 1986. Synthesis of fusion and mature murine alpha interferons in *Escherichia coli*. *Gene* **45**:317-325.
- King, P., and S. Goodbourn. 1994. The beta-interferon promoter responds to priming through multiple independent regulatory elements. *J. Biol. Chem.* **269**:30609-30615.
- Lin, R., C. Heylbroeck, P. M. Pitha, and J. Hiscott. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. *Mol. Cell. Biol.* **18**:2986-2996.
- Magin, T. M., J. McWhir, and D. W. Melton. 1992. A new mouse embryonic stem cell line with good germ line contribution and gene targeting frequency. *Nucleic Acids Res.* **20**:3795-3796.
- Marie, I., J. E. Durbin, and D. E. Levy. 1998. Differential viral induction of distinct interferon-a genes by positive feedback through interferon regulatory factor-7. *EMBO J.* **17**:6660-6669.
- Naramura, M., R. J. Hu, and H. Gu. 1998. Mice with a fluorescent marker for interleukin 2 gene activation. *Immunity* **9**:209-216.
- Pavlovic, J., A. Schroder, A. Blank, F. Pitossi, and P. Staeheli. 1993. Mx proteins: GTPases involved in the interferon-induced antiviral state. *Ciba Found. Symp.* **176**:233-243.
- Pilon, M., M. Gullberg, and E. Lundgren. 1991. Transient expression of the CD2 cell surface antigen as a sortable marker to monitor high frequency transfection of human primary B cells. *J. Immunol.* **146**:1047-1051.
- Pitha, P. M., and W. C. Au. 1995. Induction of interferon alpha genes expression. *Semin. Virol.* **6**:151-159.
- Platanius, L. C., P. Domanski, O. W. Nadeau, T. Yi, S. Uddin, E. Fish, B. G. Neel, and O. R. Colamonic. 1998. Identification of a domain in the beta subunit of the type I interferon (IFN) receptor that exhibits a negative regulatory effect in the growth inhibitory action of type I IFNs. *J. Biol. Chem.* **273**:5577-5581.
- Platanius, L. C., S. Uddin, P. Domanski, and O. R. Colamonic. 1996. Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor. *J. Biol. Chem.* **271**:23630-23633.
- Prasher, D. C. 1995. Using GFP to see the light. *Trends Genet.* **11**:320-323.
- Rani, M. R. S., G. R. Foster, S. Leung, D. Leaman, G. R. Stark, and R. M. Ransohoff. 1996. Characterization of beta-R1, a gene that is selectively

- induced by interferon beta (IFN-beta) compared with IFN-alpha. *J. Biol. Chem.* **271**:22878–22884.
32. **Riviere, I., M. J. Sunshine, and D. R. Littman.** 1998. Regulation of IL-4 expression by activation of individual alleles. *Immunity* **9**:217–228.
 33. **Runkel, L., L. Pfeffer, M. Lewerenz, D. Monneron, C. H. Yang, A. Murti, S. Pellegrini, S. Goelz, G. Uze, and K. Mogensen.** 1998. Differences in activity between alpha and beta type I interferons explored by mutational analysis. *J. Biol. Chem.* **273**:8003–8008.
 34. **Samuel, C. E.** 1991. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. *Virology* **183**:1–11.
 35. **Sato, M., N. Tanaka, N. Hata, E. Oda, and T. Taniguchi.** 1998. Involvement of the IRF family transcription factor IRF-3 in virus-induced activation of the IFN-beta gene. *FEBS Lett.* **425**:112–116.
 36. **Savage, P., V. Horton, J. Moore, M. Owens, P. Witt, and M. E. Gore.** 1996. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. *Br. J. Cancer* **74**:1482–1486.
 37. **Schafer, S. L., R. Lin, P. A. Moore, J. Hiscott, and P. M. Pitha.** 1998. Regulation of type I interferon gene expression by interferon regulatory factor-3. *J. Biol. Chem.* **273**:2714–2720.
 38. **Sen, G. C., and R. M. Ransohoff.** 1993. Interferon-induced antiviral actions and their regulation. *Adv. Virus Res.* **42**:57–102.
 39. **Smith, G. L., J. A. Symons, and A. Alcami.** 1998. Poxviruses: interfering with interferon. *Semin. Virol.* **8**:409–418.
 40. **Smith, G. L., J. A. Symons, A. Khanna, A. Vanderplassen, and A. Alcami.** 1997. Vaccinia virus immune evasion. *Immunol. Rev.* **159**:137–154.
 41. **Suzuki, F., N. Ishida, T. Sato, and S. Suzuki.** 1975. Effect of the interferon inducer, dextran phosphate, on influenza virus infection in mice. *Proc. Soc. Exp. Biol. Med.* **149**:1069–1075.
 42. **Symons, J. A., A. Alcami, and G. L. Smith.** 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. *Cell* **81**:551–560.
 43. **van den Broek, M. F., U. Muller, S. Huang, M. Aguet, and R. M. Zinkernagel.** 1995. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. *J. Virol.* **69**:4792–4796.
 44. **van den Broek, M. F., U. Muller, S. Huang, R. M. Zinkernagel, and M. Aguet.** 1995. Immune defence in mice lacking type I and/or type II interferon receptors. *Immunol. Rev.* **148**:5–18.
 45. **Wathelet, M. G., C. H. Lin, B. S. Parekh, L. V. Ronco, P. M. Howley, and T. Maniatis.** 1998. Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. *Mol. Cell* **1**:507–518.
 46. **Wurst, W., and A. L. Joyner.** 1993. Production of targeted embryonic stem cell clones, p. 33–61. *In* A. L. Joyner (ed.), *Gene targeting: a practical approach*. IRL Press, Oxford, United Kingdom.
 47. **Yoneyama, M., W. Suhara, Y. Fukuhara, M. Fukuda, E. Nishida, and T. Fujita.** 1998. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. *EMBO J.* **17**:1087–1095.